

Freedom of Information Request	FOI 22-418	12 <sup>th</sup> September 2022
--------------------------------	------------	---------------------------------

**I would like to please request the following information with regards to Breast Cancer Treatment, on behalf of Novartis.**

**The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.**

**Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:**

- **Abemaciclib (Verzenios) + aromatase inhibitor \***
- **Abemaciclib (Verzenios) + Fulvestrant (Faslodex)**
- **Alpelisib (Piqray) + Fulvestrant (Faslodex)**
- **Atezolizumab (Tecentriq)\*\***
- **Bevacizumab (Avastin)**
- **Eribulin (Halaven)**
- **Everolimus (Afinitor) + Exemestane**
- **Fulvestrant (Faslodex) as a single agent**
- **Gemcitabine + paclitaxel**
- **Herceptin (Trastuzumab) + paclitaxel**
- **Herceptin (Trastuzumab) as a single agent**
- **Lapatinib (Tyverb)**
- **Neratinib (Nerlynx)**
- **Olaparib (Lynparza)**
- **Palbociclib (Ibrance) + aromatase inhibitor\***
- **Palbociclib (Ibrance) + Fulvestrant (Faslodex)**
- **Pertuzumab (Perjeta) + trastuzumab + docetaxel**
- **Ribociclib (Kisqali) + aromatase inhibitor\***
- **Ribociclib (Kisqali) + Fulvestrant (Faslodex)**
- **Talazoparib (Talzenna)**
- **Trastuzumab emtansine (Kadcyla)**
- **Other active systemic anti-cancer therapy \*\***

**\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

**\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent**

The Health Board does not hold this information and would advise you to contact [Velindre University Health Board](#).

**Q2. For the above patients, how many of these received their first ever dose for each product line?**

As per Q1.